Acquiring Company
FutureTech II Acquisition
Acquired Company
Longevity Biomedical
Description
FutureTech II Acquisition Corp. has entered into a merger agreement with Longevity Biomedical Inc. The merger will transform Longevity into a wholly-owned subsidiary. The combined company is expected to list on Nasdaq under the symbol 'LBIO'. This move aligns with FutureTech's strategy of targeting innovative companies in the technology sector.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed